Eli Lilly (NYSE: LLY) has announced agreements to acquire three private companies — Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc. — in transactions that could total up to USD 3.83 billion in cash. The deals mark Lilly's expansion into vaccine-based infectious disease prevention.
The three deals are structured as outright acquisitions, each comprising an upfront payment and contingent milestone payments, with individual upfront amounts undisclosed. Washington-based Curevo shareholders could receive up to USD 1.5 billion, contingent on an upfront payment and one specified milestone. Shareholders of the Switzerland-based LimmaTech could receive up to USD 780 million, with additional payments tied to clinical and regulatory milestones. And Maryland-based Vaccine Company shareholders could receive up to USD 1.55 billion, with subsequent payments linked to clinical and commercial milestones. All transactions are subject to Hart-Scott-Rodino antitrust review and customary closing conditions.
Curevo's lead asset, amezosvatein, is an adjuvanted subunit shingles vaccine in Phase II development engineered with a next-generation synthetic adjuvant intended to improve tolerability relative to the current standard of care. In a head-to-head Phase II trial, amezosvatein matched immune response across all primary endpoints while reducing activity-limiting fatigue, chills, and injection-site pain by more than half.
LimmaTech's lead program, LTB-SA7, is a Phase I vaccine targeting Staphylococcus aureus, the leading cause of surgical-site infection; the company's platform is designed to elicit broad immune responses by targeting bacterial toxins and superantigens. Multiple prior S. aureus vaccine programs have failed in late-stage development, making the indication one of the more challenging targets in bacterial vaccinology.